Kahler M, Schwaiger A, Mühlberger V, Moes N, Ludescher C, Dietze O, Knapp E
Univ.-Klinik für Innere Medizin Innsbruck.
Z Kardiol. 1990 Nov;79(11):748-52.
According to morphological criteria of the myocardium, patients with clinical and hemodynamic signs of dilated cardiomyopathy were divided into three groups. Group I: patients with 1-2 mitochondria per 2 sarcomeres (n = 46); Group II: patients with more than 2 mitochondria per 2 sarcomeres (n = 47); Group III: patients with histological findings of myocarditis in the past (n = 33). Mean follow-up in groups I, II, III was 29, 22, 26 months, respectively (6-58, 3-52, 3-62/median 29, 18, 22). Clinical parameters were evaluated at the beginning and at the end of the prospective observation and were classified clinically as "improved, unchanged, deteriorated"; "heart transplantation", "death of cardial causes", "death of other than cardial causes" or "lost to follow up" were the other endpoints of the observation. At the beginning there were no hemodynamic differences between groups I, II, III, except significant difference in ejection fraction and mean ventricular shortening velocity between groups I and II. Scored together with the clinical symptoms "deterioration" and "death of cardial causes" as endpoints, survival rates without event up to 5 years in group I were 83 +/- 7% compared with group II 33 +/- 13% and group III 86 +/- 8%. There were significant differences (p less than 0.01). We conclude that the increased number of mitochondria per 2 sarcomeres in biopsy specimen of patients with dilated cardiomyopathy can be a significant parameter of deteriorated prognosis.
根据心肌的形态学标准,将有扩张型心肌病临床和血流动力学体征的患者分为三组。第一组:每2个肌节有1 - 2个线粒体的患者(n = 46);第二组:每2个肌节有2个以上线粒体的患者(n = 47);第三组:既往有心肌炎组织学表现的患者(n = 33)。第一组、第二组、第三组的平均随访时间分别为29个月、22个月、26个月(6 - 58个月、3 - 52个月、3 - 62个月/中位数29个月、18个月、22个月)。在前瞻性观察开始和结束时评估临床参数,并临床分类为“改善、不变、恶化”;“心脏移植”、“心脏原因死亡”、“非心脏原因死亡”或“失访”是观察的其他终点。开始时,第一组、第二组、第三组之间除第一组和第二组在射血分数和平均心室缩短速度上有显著差异外,血流动力学无差异。将“恶化”和“心脏原因死亡”作为终点与临床症状一起计分,第一组5年无事件生存率为83±7%,第二组为33±13%,第三组为86±8%。存在显著差异(p<0.01)。我们得出结论,扩张型心肌病患者活检标本中每2个肌节线粒体数量增加可能是预后恶化的一个重要参数。